yue wang

Dr. yue wang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
SSSensen Su
Sensen Su
WWWanning Wang
Wanning Wang
TSTao Sun
Tao Sun
FMFuzhe Ma
Fuzhe Ma
YWyue wang
yue wang
ZXZhong-Gao Xu
Zhong-Gao Xu

31 May 2023 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
XFXixi Fan
Xixi Fan
FWFei Wang
Fei Wang
HSHongxiao Song
Hongxiao Song
FXFengchao Xu
Fengchao Xu
XLXiaolu Li
Xiaolu Li
GTGuangyun Tan
Guangyun Tan
Baicalin, which is a key bioactive constituent obtained from Scutellaria baicalensis, has been utilized in traditional Chinese medicine for many centuries. Although it has been reported that Baicalin (BA) can inhibit the replication of the Hepatitis B virus (HBV), the exact mechanism behind this process remains unclear. Interferon-stimulated genes (ISGs) are crucial in the process of antiviral defense. We aim to investigate whether BA can regulate the expression of ISGs, and thereby potentially modulate the replication of HBV. The study involved the use of CRISPR/Cas9 technology to perform knockout experiments on TRIM25 and IFIT3 genes. The expression of these genes was confirmed through techniques such as immunoblotting or Q-PCR. The levels of HBsAg and HBeAg were measured using ELISA, and the expression of interferon-stimulated genes was detected using a luciferase assay. It is interesting to note that several ISGs belonging to the TRIM family, including TRIM5, TRIM25, and TRIM14, were induced after BA treatment. On the other hand, members of the IFIT family were reduced by BA stimulation. Additionally, BA-mediated HBV inhibition was found to be significantly restored in HepG2 cells where TRIM25 was knocked out. Additional research into the mechanism of action of BA found that prolonged treatment with BA activated the JAK/STAT signaling pathway while simultaneously inhibiting the NF-kB pathway. The findings of our study indicate that TRIM25 has a significant impact on the regulation of HBV replication following BA treatment, providing additional insight into the mechanisms by which BA exerts its antiviral effects.

1 January 2021 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
PDF file
LXLu Xue
Lu Xue
CLChunhuai Li
Chunhuai Li
JRJin Ren
Jin Ren
YWyue wang
yue wang
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm, in which relapse due to drug resistance is the main cause for treatment failure and the disease progression. In this study, we aimed to investigate the molecular mechanism of KDM4C-dependent MALAT1/miR-328-3p/CCND2 axis in cytarabine (Ara-C) resistance in the context of AML. Bioinformatics analysis was performed to predict the targeting relationships among KDM4C, MALAT1, miR-328-3p, and CCND2 in AML, which were validated with chromatin immunoprecipitation and dual-luciferase reporter assay. Methylation-specific polymerase chain reaction was conducted to detect the methylation of MALAT1 promoter. After conducting gain- and loss-of-function assays, we investigated the effect of KDM4C on cell Ara-C resistance. A NOD/SCID mouse model was established to further investigate the roles of KDM4C/MALAT1/miR-328-3p/CCND2 in Ara-C resistant AML cells. KDM4C expression was upregulated in AML. KDM4C upregulation promoted the demethylation in the promoter region of MALAT1 to increase its expression, MALAT1 targeted and inhibited miR-328-3p expression, enhancing the Ara-C resistance of HL-60/A. miR-328-3p targeted and suppressed the expression of CCND2 in HL-60/A to inhibit the Ara-C resistance. Mechanistically, KDM4C regulated miR-328-3p/CCND2 through MALAT1, resulting in Ara-C resistance in AML. Findings in an in vivo xenograft NOD/SCID mouse model further confirmed the contribution of KDM4C/MALAT1/miR-328-3p/CCND2 in the Ara-C resistant AML. Our study demonstrated that KDM4C may up-regulate MALAT1 expression, which decreases the expression of miR-328-3p. The downregulation of miR-328-3p increased the level of CCND2, which induced the Ara-C resistance in AML.

1 January 2022 in Experimental Hematology
Verified
Journal Article
Closed access
FLFangbing Liu
Fangbing Liu
QZQiushi Zhao
Qiushi Zhao
YSYongwei Su
Yongwei Su
JLJing Lv
Jing Lv
YGYuqing Gai
Yuqing Gai
GWGuan Wang
Guan Wang

3 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
SWShuangshuang Wu
Shuangshuang Wu
HEHolly Edwards
Holly Edwards
DWDeying Wang
Deying Wang
SLShuang Liu
Shuang Liu
XQXinan Qiao
Xinan Qiao
Yubin GeYubin Ge
Yubin Ge
FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3-ITD) mutations occur in about 25% of all acute myeloid leukemia (AML) patients and confer a poor prognosis. FLT3 inhibitors have been developed to treat patients with FLT3-mutated AML and have shown promise, though the acquisition of resistance occurs, highlighting the need for combination therapies to prolong the response to FLT3 inhibitors. In this study, we investigated the selective Mcl-1 inhibitor AZD5991 in combination with the FLT3 inhibitors gilteritinib and MRX-2843. The combinations synergistically induce apoptosis in AML cell lines and primary patient samples. The FLT3 inhibitors downregulate c-Myc transcripts through the suppression of the MEK/ERK and JAK2/STAT5 pathways, resulting in the decrease in c-Myc protein. This suppression of c-Myc plays an important role in the antileukemic activity of AZD5991. Interestingly, the suppression of c-Myc enhances AZD5991-inudced cytochrome c release and the subsequent induction of apoptosis. AZD5991 enhances the antileukemic activity of the FLT3 inhibitors gilteritinib and MRX-2843 against FLT3-mutated AML in vitro, warranting further development.

24 June 2024 in Leukemia Research
Verified
Journal Article
Closed access
SWShuangshuang Wu
Shuangshuang Wu
FLFangbing Liu
Fangbing Liu
YGYuqing Gai
Yuqing Gai
JCJenna Carter
Jenna Carter
HEHolly Edwards
Holly Edwards
Yubin GeYubin Ge
Yubin Ge